Pfizer, Inc. News

Do you have an interest in the products developed by Pfizer, Inc., or are you interested in the performance of the company? If you are you should register for the free Pfizer, Inc. news email from Wiser. Pfizer, Inc. is an American-based pharmaceutical company that researches, develops and manufactures medicines and vaccines. The products developed by the company are used all over the world. They include leading brands like Lipitor, Zithromax and Viagra. The company was founded in 1849 and today is one of the largest pharmaceutical companies in the world. Its current chairman and CEO is Ian Reed. Most analysts expect Pfizer, Inc. to expand through acquisitions over the coming years. The Wiser daily Pfizer, Inc. news email covers this news as well as analysis on the performance of the company, and details about its products. These articles come from the best sources around the web and are delivered in a comprehensive but simple to use format. Sign up today.

Recent Pfizer, Inc. News Coverage
 
Your Weekly Recommendations Monday, February 19, 2018
 
Recommended for you
3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb
TheStreet • Bret Kenwell
Remicade biosims from Pfizer, Merck unlikely to turn the tide in 2018: analyst
FiercePharma • Eric Sagonowsky
Wall Street opens lower as financial, tech stocks weigh
Reuters • Noel Randewich
Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q4 2017 Update
Seeking Alpha • John Vincent
Bosulif Drug Analysis 2018: A Kinase Inhibitor that Targets the BCR-ABL Kinase and Also Inhibits the SRC-Family Kinases that Include SRC, LYN, and HCK - ResearchAndMarkets.com
BusinessWire
Futures rise, setting stocks on firm ground for the week
Reuters • Noel Randewich
New Tax Cuts Will Save Billions. But for Whom?
Fortune Magazine • Geoff Colvin
Global Amyloidosis Market Spotlight 2017-2027 - ResearchAndMarkets.com
BusinessWire
Top Ten most popular articles on Pharmafile.com this week
Pharmafile
How to Invest in the S&P 500 ETF
ETF Trends • Ong Kai Kiat
 
Recommended for You
Biotechnology, Pfizer, Inc.
3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb
TheStreetBret Kenwell
Shares of Bristol-Myers Squibb Co. (BMY - Get Report) shot out of a cannon Thursday, racing higher by 5.55% to $68.98. Earlier this month the company beat on earnings per share and revenue expectations, but it was a new price target that...
Share
Johnson & Johnson, Merck & Co., Inc.
Remicade biosims from Pfizer, Merck unlikely to turn the tide in 2018: analyst
FiercePharmaEric Sagonowsky
Pfizer hasn't gained much market share with Inflectra, its biosimilar of Johnson & Johnson's Remicade, since its U.S. launch back in 2016. The company's CEO Ian Read recently said Inflectra is picking up increased commercial coverage, but an analyst figures the biosimilar's...
Share
Elections & Polls, Finance
Wall Street opens lower as financial, tech stocks weigh
ReutersNoel Randewich
NEW YORK () - The S&P 500 rose marginally on Friday to mark its biggest weekly increase in five years, although earlier gains evaporated after the indictment of Russians for meddling in the 2016 presidential election sent investors into defensive mode before...
Share
Finance, Investment Industry
Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q4 2017 Update
Seeking AlphaJohn Vincent
Summary Prem Watsa's 13F portfolio value increased ~16% from $1.22B to $1.42B this quarter. Fairfax Financial's largest five stakes are Blackberry, Resolute Forest Products, Kennedy Wilson, Intrepid Potash, and USG. They together account for ~85% of the US long assets. The 13F...
Share
Cancer, Novartis AG
Bosulif Drug Analysis 2018: A Kinase Inhibitor that Targets the BCR-ABL Kinase and Also Inhibits the SRC-Family Kinases that Include SRC, LYN, and HCK - ResearchAndMarkets.com
BusinessWire
DUBLIN--(BUSINESS WIRE)--The "Drug analysis: Bosulif" drug pipelines has been added to ResearchAndMarkets.com's offering. Bosulif (bosutinib; Pfizer) is a kinase inhibitor that targets the BCR-ABL kinase and also inhibits the Src-family kinases that include Src, Lyn, and Hck. The BCR-ABL kinase is upregulated...
Share
Elections & Polls, Pfizer, Inc.
Futures rise, setting stocks on firm ground for the week
ReutersNoel Randewich
NEW YORK () - The S&P 500 rose marginally on Friday to mark its biggest weekly increase in five years, although earlier gains evaporated after the indictment of Russians for meddling in the 2016 presidential election sent investors into defensive mode before...
Share
Economic Policy, Labor Policy
New Tax Cuts Will Save Billions. But for Whom?
Fortune MagazineGeoff Colvin
Headlines dripped with scorn when Kimberly-Clark (kmb, +0.27%) announced in January that it would lay off 5,000 to 5,500 employees. The company “celebrates the Trump tax cuts with massive layoffs, share buybacks,” said Salon, and will “use savings from tax cuts to...
Share
GlaxoSmithKline plc, Pfizer, Inc.
Global Amyloidosis Market Spotlight 2017-2027 - ResearchAndMarkets.com
BusinessWire
DUBLIN--(BUSINESS WIRE)--The "Market Spotlight: Amyloidosis" report has been added to ResearchAndMarkets.com's offering. This Market Spotlight report covers the amyloidosis market, comprising key pipeline and marketed drugs, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals....
Share
Biotechnology, Merck & Co., Inc.
Top Ten most popular articles on Pharmafile.com this week
Pharmafile
Another week is finished and it's been a disastrous one for research into a potential treatment for Alzheimer’s disease. Two of our top ten stories are, unfortunately, regarding the failure of late-stage candidates for treatment that have been dropped and another where...
Share
Finance, Investment Industry
How to Invest in the S&P 500 ETF
ETF TrendsOng Kai Kiat
The SPDR S&P 500 ETF (NYSE: SPY) is the oldest and most successful ETF in the world and tracks 500 of the most successful companies in the United States across various sectors. In my opinion, SPY is the most cost-effective method to...
Share